Evolocumab
Phase 1UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Metabolic Effects of Evolocumab and Atorvastatin
Conditions
Acute Metabolic Effects of Evolocumab and Atorvastatin
Trial Timeline
Feb 1, 2024 → Dec 1, 2025
NCT ID
NCT06140095About Evolocumab
Evolocumab is a phase 1 stage product being developed by Amgen for Acute Metabolic Effects of Evolocumab and Atorvastatin. The current trial status is unknown. This product is registered under clinical trial identifier NCT06140095. Target conditions include Acute Metabolic Effects of Evolocumab and Atorvastatin.
What happened to similar drugs?
20 of 20 similar drugs in Acute Metabolic Effects of Evolocumab and Atorvastatin were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (17)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06140095 | Phase 1 | UNKNOWN |
| NCT04539223 | Approved | UNKNOWN |
| NCT03944577 | Phase 2 | Completed |
| NCT03331666 | Approved | Terminated |
| NCT03403374 | Approved | Completed |
| NCT03096288 | Approved | Completed |
| NCT03080935 | Phase 3 | Terminated |
| NCT02957604 | Pre-clinical | Terminated |
| NCT02624869 | Phase 3 | Completed |
| NCT02867813 | Phase 3 | Completed |
| NCT02585895 | Phase 3 | Completed |
| NCT02304484 | Phase 3 | Completed |
| NCT02275156 | Phase 1 | Completed |
| NCT01652703 | Phase 2 | Completed |
| NCT01624142 | Phase 2/3 | Completed |
| NCT01439880 | Phase 2 | Completed |
| NCT01380730 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Metabolic Effects of Evolocumab and Atorvastatin